ASCO 2009: Bevacizumab and standard adjuvant chemotherapy: no improvement in dis...
Steven K. Cheng, phd - Oregon Health and Science University, Oregan, USA. ASCO p...
Dr. Vincent O. Dezentjé - Leiden University Medical Center, Leiden, The Netherl...
Eric Van Cutsem, MD, phd, University Hospital Gasthuisberg, Leuven, Belgium, spe...
ASCO 2009: Rowan T. Chlebowski, MD, phd - Harbor-UCLA Medical Center - Los Angel...
ecancertv |
(0) (0 Votes)
|
Views: (619) Date: (07-04-10) Time: (00:03:12) |
Description: Dr. Vincent A. Miller - MD Memorial Sloan-Kettering Cancer Center, New York, USA ASCO press conference: A phase III trial finds that adding erlotinib (Tarceva) to bevacizumab-based (Avastin) maintenance therapy in patients with advanced NSCLC delays cancer progression more than maintenance treatment with bevacizumab alone.